Cumberland Pharmaceuticals Inc. CPIX
5.37 USD +0.15 (+2.87%)
At closeNov 10, 2026, 6:11 AM EST
5.01 -0.36 -6.70%
Pre-market · Nov 10, 6:11 AM ET
5.21 Day range 5.52
1.85 52-week range 9.28
- YTD
- +34.92%
- 1 year
- +152.11%
News
defenseworld.net United-Guardian (NASDAQ:UG) versus Cumberland Pharmaceuticals (NASDAQ:CPIX) Financial Survey Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and United-Guardian (NASDAQ: UG - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will…
prnewswire.com CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS NASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases,…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
benzinga.com Cumberland Pharmaceuticals Intends To File New Drug Application To FDA For Ifetroban To Treat Cardiomyopathy Associated With Duchenne Muscular Dystrophy Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Pomdoctor (NASDAQ:POM) shares rose 25.6% to $1.47 during Friday's after-market session. The market value of their outstanding shares is at $8.3 million. GeneDx Holdings (NASDAQ:WGS) shares…
benzinga.com Cumberland Pharmaceuticals Announces Data From Its Phase 2 ASSIST-SSc Study Of Oral Ifetroban For Patients With Systemic Sclerosis; Gastrointestinal Adverse Events Were More Frequent In Ifetroban Group Than Placebo; Majority Of Patients Demonstrated Limited Disease Progression, Which Reduced Ability To Track Treatment Difference Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from…